Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that on 28 April 2026 it repurchased 540,000 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.50 to HKD 3.58, for an aggregate consideration of HKD 1.91 million. The volume-weighted average price stood at HKD 3.5367 per share.

Following the transaction, issued shares outstanding (excluding treasury shares) fell by 0.0121 % to 4,468.91 million, while treasury shares increased to 53.43 million. Total issued share capital remained unchanged at 4,522.33 million shares.

The buyback formed part of a mandate approved on 27 May 2025 that authorises the repurchase of up to 451.56 million shares. Including the latest purchase, 46.78 million shares—equivalent to 10.36 % of the share capital on the mandate’s approval date—have been repurchased under this authority.

No repurchased shares have been cancelled; all 540,000 shares acquired on 28 April 2026 are being held as treasury shares. In accordance with Hong Kong listing rules, Weigao Group is subject to a moratorium on issuing new shares or transferring treasury shares until 29 May 2026.